<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01085136</url>
  </required_header>
  <id_info>
    <org_study_id>1200.42</org_study_id>
    <secondary_id>2009-014563-39</secondary_id>
    <nct_id>NCT01085136</nct_id>
  </id_info>
  <brief_title>LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib</brief_title>
  <official_title>Phase III Randomized Trial of BIBW 2992 Plus Weekly Paclitaxel Versus Investigator's Choice of Chemotherapy Following BIBW 2992 Monotherapy in Non-small Cell Lung Cancer Patients Failing Previous Erlotinib or Gefitinib Treatment (LUX Lung 5)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this randomized, open-label, active-controlled, multi-center trial
      is to determine the efficacy of BIBW 2992 given as an add-on to chemotherapy in patients with
      NSCLC Stage IIIb or IV progressing after BIBW 2992 monotherapy compared to chemotherapy alone
      in this patient population. Patients on both treatment arms will receive best supportive care
      in addition to study treatment. Patients enrolled into the trial will be treated and followed
      until death or lost to follow-up. Additional information on the health-related quality of
      life (HRQOL) will be collected.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (Part B)</measure>
    <time_frame>From randomization until disease progression or death; Up to 32 months</time_frame>
    <description>Progression free survival (PFS) time as determined by Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 from day of randomization until disease progression or death for patients randomised to combination therapy with afatinib plus paclitaxel or to investigator's choice of chemotherapy.
Median was calculated from the Kaplan−Meier curve.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (Part A)</measure>
    <time_frame>From first dose administration until disease progression or death; Up to 51 months</time_frame>
    <description>Progression free survival (PFS) as determined by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 for Part A.
Median was calculated from the Kaplan−Meier curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (Part B)</measure>
    <time_frame>From randomization until death; Up to 32 months</time_frame>
    <description>Overall survival (OS) as determined by the time from randomization to death in part B.
Median was calculated from the Kaplan−Meier curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response (Part A)</measure>
    <time_frame>Post baseline tumour-imaging was performed at every 6 weeks thereafter until disease progression; upto 51 months</time_frame>
    <description>Objective response defined as the best overall response of complete response [CR]: disappearance of all target lesion &amp; partial response [PR]: ≥30% decrease in the sum of the longest diameter of target lesions , taking as reference the baseline sum longest diameter of Afatinib monotherapy according to RECIST 1.1 for Part A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response (Part B)</measure>
    <time_frame>Post baseline tumour-imaging was performed at every 8 weeks thereafter until disease progression; up to 32 Months</time_frame>
    <description>Objective response (CR, PR) of Afatinib/paclitaxel combination therapy and comparator chemotherapy in Part B after progression in Part A according to RECIST 1.1 .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity and Incidence of Adverse Events (AEs) for Part A &amp; Part B.</measure>
    <time_frame>From first administration of treatment until 28 days after last drug administration, up to 51 Months (Part A) and from randomization until 28 days after last drug administration of Trial medication, up to 32 Months (Part B)</time_frame>
    <description>Safety of Afatinib as indicated by intensity and incidence of adverse events, graded according to United States National Cancer Institute Common terminology Criteria for Adverse Events (US NCI CTCAE) Version 3.0 both for Part A and Part B. The CTCAE grades are: 1 (mild AE), 2 (moderate AE), 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related to AE).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1154</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Investigator`s choice of chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be treated with investigator`s choice of chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBW 2992 and Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with BIBW 2992daily with a medium dose and weekly administration of Paclitaxel at a dose of 80 mg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Investigator´s choice of chemotherapy</intervention_name>
    <description>BIBW 2992 in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy</description>
    <arm_group_label>Investigator`s choice of chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBW 2992</intervention_name>
    <description>BIBW 2992 will be given in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy</description>
    <arm_group_label>BIBW 2992 and Paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Part A

          1. Patients with pathologically confirmed diagnosis of NSCLC Stage IIIB (with
             cytologically proven pleural effusion or pericardial effusion) or Stage IV who have
             failed treatment with erlotinib (Tarceva) or gefitinib (Iressa).

          2. Patients should have received and failed at least one line of cytotoxic chemotherapy
             including a platinum-based regimen in patients eligible for platinum-based therapy and
             pemetrexed in pemetrexed eligible patients (unless pemetrexed is not considered a
             regulatory or clinical standard of care e.g. no label indication, no availability or
             no coverage by 3rd party payer(s)) for advanced or metastatic disease and have
             progressive disease following at least 12 weeks of treatment with erlotinib or
             gefitinib

          3. Patients pretreated with taxane-based chemotherapy for advanced or metastatic disease
             must have experienced stable disease, partial or complete response as best response

          4. Eastern Cooperative Oncology Group performance Score 0 or 1.

          5. Patients with at least one tumor lesion that can accurately be measured by magnetic
             resonance imaging (MRI), or computed tomography (CT) in at least one dimension with
             longest diameter to be recorded as 10 mm but no less than double the slice thickness
             according to RESIST 1.1.

          6. Male and female patients no less than 18 years of age.

          7. Life expectancy of at least three (3) months.

          8. Written informed consent that is consistent with ICH-GCP guidelines. Part B 1)
             Clinical benefit (disease stabilization or antitumor response) of 12 weeks duration in
             Part A of the trial determined on the second tumour assessment.

        2.) Patients should have progressed in Part A according to RECIST 1.1 3.) New informed
        consent, including consent to biomarker sampling, must be signed before patients enter Part
        B of the trial

        Exclusion criteria:

          1. Previous treatment with BIBW 2992

          2. Chemo-, hormone- (other than megestrol acetate, steroids required for maintenance
             non-cancer therapy or as premedication before chemotherapy) or immunotherapy within
             the past 4 weeks; except for TKI pretreatment (2 weeks only)

          3. Active/symptomatic brain metastases including leptomeningeal disease. Patients with a
             history of treated brain metastasis must have a stable or normal brain MRT/CT scan at
             screening and be at least 4 weeks post-radiation or surgery for brain metastasis.
             Dexamethasone therapy will be allowed if administered as a stable dose for at least
             one month before randomization.

          4. Significant or recent acute gastrointestinal disorders with diarrhea as a major
             symptom e.g., Crohn's disease, mal-absorption, or CTCAE Grade &gt;2 diarrhea of any
             etiology at baseline

          5. Patients who have any other life-threatening illness or organ system dysfunction,
             which in the opinion of the Investigator, would either compromise patient safety or
             interfere with the evaluation of the safety of the test drug

          6. Other malignancies diagnosed within the past five (5) years (other than
             non-melanomatous skin cancer and in situ cervical cancer)

          7. Radiotherapy within the past 2 weeks prior to treatment with the trial drug

          8. History or presence of clinically relevant cardiovascular abnormalities such as
             uncontrolled hypertension, congestive heart failure New york Heart Association (NYHA)
             functional classification of 3, unstable angina, or poorly controlled arrhythmia.
             Myocardial infarction within 6 months prior to entering the trial.

          9. Cardiac left ventricular function with resting ejection fraction of less than 50%
             measured by multigated blood pool imaging of the heart (MUGA scan) or echocardiogram .

         10. Prior treatment with anthracyclines with a cumulative dose of doxorubicin (or
             equivalent) at or greater than 400 mg/m2

         11. Absolute neutrophil count (ANC) at or less than 1500 / mm3

         12. Platelet count at or less than 100,000 / mm3

         13. Bilirubin at or greater than 1.5 mg / dL (&gt;26 mol / L, SI unit equivalent)

         14. Aspartate amino transferase (AST) or alanine amino transferase (ALT) at or greater
             than three times the upper limit of normal (if related to liver metastases at or
             greater than five times the upper limit of normal)

         15. Serum creatinine at or greater 1.5 times the upper normal limit or calculated/measured
             creatinine clearance at or less than 45 mL/min

         16. Women of child-bearing potential or men who are able to father a child unwilling to
             use a medically acceptable method of contraception during the trial

         17. Pregnancy or breast feeding

         18. Patients unable to comply with the protocol

         19. Patients with any serious active infection including known human immunodeficiency
             virus (HIV), active hepatitis B or active hepatitis C

         20. Known or suspected active drug or alcohol abuse

         21. Pre-existing or current Interstitial lung disease (ILD) 22.)

         22. Peripheral polyneuropathy of &gt; Grade 2

         23. Requirement for treatment with any of the pohibited concomitant medication listed in
             section 4.2.2.1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wodonga</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Duffel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Louvière</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Middelheim</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ottignies</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bayonne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Caen Cedex 5</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Tronche</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lyon Cedex 08</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris cedex 20</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint-Herblain cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Esslingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gauting</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Törökbálint</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maharashtra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nashik, Maharashtra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aviano (PN)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Monza (mi)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hwasun</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Distrito Federal</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arequipa</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Victoria</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Olsztyn</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Otwock</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Obninsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mataró</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dnipropetrovks</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maidstone</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sutton, Surrey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Truro, Cornwall</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>China</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2010</study_first_submitted>
  <study_first_submitted_qc>March 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2010</study_first_posted>
  <results_first_submitted>October 1, 2014</results_first_submitted>
  <results_first_submitted_qc>October 1, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 3, 2014</results_first_posted>
  <last_update_submitted>February 15, 2017</last_update_submitted>
  <last_update_submitted_qc>February 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>PD = Progression Disease</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Afatinib Monotherapy (Part A)</title>
          <description>Afatinib 50 mg film-coated tablet was orally administered once daily of each 28-day treatment course, with dose reductions to 40 mg/day and 30 mg/day (following the protocol-defined dose reduction scheme).</description>
        </group>
        <group group_id="P2">
          <title>Afatinib Plus Paclitaxel (Part B)</title>
          <description>Afatinib 40 mg film-coated tablet dose was orally administered once daily of each 28-day treatment course, with dose reductions to 30 mg/day and 20 mg/day (following the protocol defined dose reduction scheme) plus paclitaxel 80 mg/m2 administered via intravenous infusion once weekly (7 weeks on/1 week off; 2 dose reductions were allowed following the protocol defined dose reduction scheme and the current local summary of product characteristics).</description>
        </group>
        <group group_id="P3">
          <title>Investigators Choice of Chemotherapy (Part B)</title>
          <description>Reference therapy for Part B dose: Depending on schedule Intravenous or oral administration (2 dose reductions were allowed following the protocol defined dose reduction scheme and the current local summary of product characteristics).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1154"/>
                <participants group_id="P2" count="0">Only Afatinib monotherapy administered in Part A</participants>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized to Part B</title>
              <participants_list>
                <participants group_id="P1" count="206">Discontinued Part A -Randomized to Part B</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="831">Randomized to Part B &amp; completed trial as per protocol, had PD, clinical progression.</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="323"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other Adverse event</title>
              <participants_list>
                <participants group_id="P1" count="223"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refusal to continue trial medication</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not defined above</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part B</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Afatinib monotherapy not administered in Part B</participants>
                <participants group_id="P2" count="138"/>
                <participants group_id="P3" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Afatinib monotherapy not administered in Part B</participants>
                <participants group_id="P2" count="87">Completed trial as per protocol, had progressive disease, clinical signs or symptoms of progression</participants>
                <participants group_id="P3" count="42">Completed trial as per protocol, had progressive disease, clinical signs or symptoms of progression</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other AE</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refusal to continue trial medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not defined above</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set, i.e. all patients who were documented to have taken at least 1 dose of afatinib 50 mg in Part A of the trial and all patients who received at least 1 dose of trial medication in Part B.</population>
      <group_list>
        <group group_id="B1">
          <title>Afatinib Monotherapy (Part A)</title>
          <description>Afatinib 50 mg film-coated tablet was orally administered once daily of each 28-day treatment course, with dose reductions to 40 mg/day and 30 mg/day (following the protocol-defined dose reduction scheme).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1154"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="741"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.1" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="654"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Eastern Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Eastern Cooperative Oncology Group (ECOG) performance score</title>
          <description>Subjects were graded based on following ECOG PS grade criteria: Grade 0: Fully active, able to carry on all pre-disease performance without restriction. Grade 1: Restricted in physically strenuous activity but ambulatory &amp; able to carry out work of a light nature. Grade 2: Ambulatory &amp; capable of all selfcare but unable to carry out any work activities. Up &amp; about more than 50% of waking hours. Grade 3: Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours. Grade 4: Completely disabled. Totally confined to bed or chair. Grade 5: Dead.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking history</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;15 pack years &amp; stopped &gt;1 year before diagnosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other current or ex−smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histologic classification</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Adenocarcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="985"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Squamous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (Part B)</title>
        <description>Progression free survival (PFS) time as determined by Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 from day of randomization until disease progression or death for patients randomised to combination therapy with afatinib plus paclitaxel or to investigator's choice of chemotherapy.
Median was calculated from the Kaplan−Meier curve.</description>
        <time_frame>From randomization until disease progression or death; Up to 32 months</time_frame>
        <population>Randomised Set: This analysis set consist of all randomised patients irrespective of whether treated or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib Plus Paclitaxel (Part B)</title>
            <description>Afatinib 40 mg film-coated tablet dose was orally administered once daily of each 28-day treatment course, with dose reductions to 30 mg/day and 20 mg/day (following the protocol defined dose reduction scheme) plus paclitaxel 80 mg/m2 administered via intravenous infusion once weekly (7 weeks on/1 week off; 2 dose reductions were allowed following the protocol defined dose reduction scheme and the current local summary of product characteristics).</description>
          </group>
          <group group_id="O2">
            <title>Investigators Choice of Chemotherapy (Part B)</title>
            <description>Reference therapy for Part B dose: Depending on schedule Intravenous or oral administration (2 dose reductions were allowed following the protocol defined dose reduction scheme and the current local summary of product characteristics).</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (Part B)</title>
          <description>Progression free survival (PFS) time as determined by Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 from day of randomization until disease progression or death for patients randomised to combination therapy with afatinib plus paclitaxel or to investigator's choice of chemotherapy.
Median was calculated from the Kaplan−Meier curve.</description>
          <population>Randomised Set: This analysis set consist of all randomised patients irrespective of whether treated or not.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.55" lower_limit="5.06" upper_limit="6.31"/>
                    <measurement group_id="O2" value="2.89" lower_limit="1.87" upper_limit="3.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio is calculated from Cox proportional hazard model with treatment as the only factor, stratified by gender and maximum duration of erlotinib or gefitinib (&lt;6 months vs &gt;=6 months).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0030</p_value>
            <p_value_desc>P−value is calculated from two−sided stratified log−rank test</p_value_desc>
            <method>stratified log−rank test</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (Part A)</title>
        <description>Progression free survival (PFS) as determined by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 for Part A.
Median was calculated from the Kaplan−Meier curve.</description>
        <time_frame>From first dose administration until disease progression or death; Up to 51 months</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib Monotherapy (Part A)</title>
            <description>Afatinib 50 mg film-coated tablet was orally administered once daily of each 28-day treatment course, with dose reductions to 40 mg/day and 30 mg/day (following the protocol-defined dose reduction scheme).</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (Part A)</title>
          <description>Progression free survival (PFS) as determined by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 for Part A.
Median was calculated from the Kaplan−Meier curve.</description>
          <population>Treated set</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.15" lower_limit="2.83" upper_limit="3.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (Part B)</title>
        <description>Overall survival (OS) as determined by the time from randomization to death in part B.
Median was calculated from the Kaplan−Meier curve.</description>
        <time_frame>From randomization until death; Up to 32 months</time_frame>
        <population>Randomised Set</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib Plus Paclitaxel (Part B)</title>
            <description>Afatinib 40 mg film-coated tablet dose was orally administered once daily of each 28-day treatment course, with dose reductions to 30 mg/day and 20 mg/day (following the protocol defined dose reduction scheme) plus paclitaxel 80 mg/m2 administered via intravenous infusion once weekly (7 weeks on/1 week off; 2 dose reductions were allowed following the protocol defined dose reduction scheme and the current local summary of product characteristics).</description>
          </group>
          <group group_id="O2">
            <title>Investigators Choice of Chemotherapy (Part B)</title>
            <description>Reference therapy for Part B dose: Depending on schedule Intravenous or oral administration (2 dose reductions were allowed following the protocol defined dose reduction scheme and the current local summary of product characteristics).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (Part B)</title>
          <description>Overall survival (OS) as determined by the time from randomization to death in part B.
Median was calculated from the Kaplan−Meier curve.</description>
          <population>Randomised Set</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.25" lower_limit="10.91" upper_limit="14.88"/>
                    <measurement group_id="O2" value="13.08" lower_limit="9.86" upper_limit="15.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio was calculated from Cox proportional hazard model with treatment as the only factor, stratified by gender and maximum duration of erlotinib or gefitinib (&lt;6 months vs &gt;=6 months).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7905</p_value>
            <method>Stratified log−rank test.</method>
            <method_desc>P−value is calculated from two−sided stratified log−rank test.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response (Part A)</title>
        <description>Objective response defined as the best overall response of complete response [CR]: disappearance of all target lesion &amp; partial response [PR]: ≥30% decrease in the sum of the longest diameter of target lesions , taking as reference the baseline sum longest diameter of Afatinib monotherapy according to RECIST 1.1 for Part A.</description>
        <time_frame>Post baseline tumour-imaging was performed at every 6 weeks thereafter until disease progression; upto 51 months</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib Monotherapy (Part A)</title>
            <description>Afatinib 50 mg film-coated tablet was orally administered once daily of each 28-day treatment course, with dose reductions to 40 mg/day and 30 mg/day (following the protocol-defined dose reduction scheme).</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response (Part A)</title>
          <description>Objective response defined as the best overall response of complete response [CR]: disappearance of all target lesion &amp; partial response [PR]: ≥30% decrease in the sum of the longest diameter of target lesions , taking as reference the baseline sum longest diameter of Afatinib monotherapy according to RECIST 1.1 for Part A.</description>
          <population>Treated set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="6.9" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response (Part B)</title>
        <description>Objective response (CR, PR) of Afatinib/paclitaxel combination therapy and comparator chemotherapy in Part B after progression in Part A according to RECIST 1.1 .</description>
        <time_frame>Post baseline tumour-imaging was performed at every 8 weeks thereafter until disease progression; up to 32 Months</time_frame>
        <population>Randomized Set</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib Plus Paclitaxel (Part B)</title>
            <description>Afatinib 40 mg film-coated tablet dose was orally administered once daily of each 28-day treatment course, with dose reductions to 30 mg/day and 20 mg/day (following the protocol defined dose reduction scheme) plus paclitaxel 80 mg/m2 administered via intravenous infusion once weekly (7 weeks on/1 week off; 2 dose reductions were allowed following the protocol defined dose reduction scheme and the current local summary of product characteristics).</description>
          </group>
          <group group_id="O2">
            <title>Investigators Choice of Chemotherapy (Part B)</title>
            <description>Reference therapy for Part B dose: Depending on schedule Intravenous or oral administration (2 dose reductions were allowed following the protocol defined dose reduction scheme and the current local summary of product characteristics).</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response (Part B)</title>
          <description>Objective response (CR, PR) of Afatinib/paclitaxel combination therapy and comparator chemotherapy in Part B after progression in Part A according to RECIST 1.1 .</description>
          <population>Randomized Set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.2" lower_limit="23.6" upper_limit="39.6"/>
                    <measurement group_id="O2" value="13.2" lower_limit="6.2" upper_limit="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Odds ratio, 95% Confidence Interval (CI) and p−value (two−sided) from logistic regression stratified for maximum treatment duration of prior erlotinib or gefitinib (&gt;=6 months vs &lt;6 months) and gender.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0065</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.980</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.357</ci_lower_limit>
            <ci_upper_limit>6.543</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensity and Incidence of Adverse Events (AEs) for Part A &amp; Part B.</title>
        <description>Safety of Afatinib as indicated by intensity and incidence of adverse events, graded according to United States National Cancer Institute Common terminology Criteria for Adverse Events (US NCI CTCAE) Version 3.0 both for Part A and Part B. The CTCAE grades are: 1 (mild AE), 2 (moderate AE), 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related to AE).</description>
        <time_frame>From first administration of treatment until 28 days after last drug administration, up to 51 Months (Part A) and from randomization until 28 days after last drug administration of Trial medication, up to 32 Months (Part B)</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib Monotherapy (Part A)</title>
            <description>Afatinib 50 mg film-coated tablet was orally administered once daily of each 28-day treatment course, with dose reductions to 40 mg/day and 30 mg/day (following the protocol-defined dose reduction scheme).</description>
          </group>
          <group group_id="O2">
            <title>Afatinib Plus Paclitaxel (Part B)</title>
            <description>Afatinib 40 mg film-coated tablet dose was orally administered once daily of each 28-day treatment course, with dose reductions to 30 mg/day and 20 mg/day (following the protocol defined dose reduction scheme) plus paclitaxel 80 mg/m2 administered via intravenous infusion once weekly (7 weeks on/1 week off; 2 dose reductions were allowed following the protocol defined dose reduction scheme and the current local summary of product characteristics).</description>
          </group>
          <group group_id="O3">
            <title>Investigators Choice of Chemotherapy (Part B)</title>
            <description>Reference therapy for Part B dose: Depending on schedule Intravenous or oral administration (2 dose reductions were allowed following the protocol defined dose reduction scheme and the current local summary of product characteristics).</description>
          </group>
        </group_list>
        <measure>
          <title>Intensity and Incidence of Adverse Events (AEs) for Part A &amp; Part B.</title>
          <description>Safety of Afatinib as indicated by intensity and incidence of adverse events, graded according to United States National Cancer Institute Common terminology Criteria for Adverse Events (US NCI CTCAE) Version 3.0 both for Part A and Part B. The CTCAE grades are: 1 (mild AE), 2 (moderate AE), 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related to AE).</description>
          <population>Treated Set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1154"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6"/>
                    <measurement group_id="O2" value="4.5"/>
                    <measurement group_id="O3" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0"/>
                    <measurement group_id="O2" value="26.1"/>
                    <measurement group_id="O3" value="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.1"/>
                    <measurement group_id="O2" value="44.0"/>
                    <measurement group_id="O3" value="38.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="9.7"/>
                    <measurement group_id="O3" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6"/>
                    <measurement group_id="O2" value="12.7"/>
                    <measurement group_id="O3" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first administration of treatment until 28 days after last drug administration, upto 51 Months (Part A) and from randomization until 28 days after last drug administration of Trial medication, upto 32 Months (Part B).</time_frame>
      <desc>Part A-events that started within the period defined by the first administration of afatinib until randomization into Part B or 28 days after the last administration of afatinib, whichever occurred first. Part B-events that started within the period from randomization through 28 days after the last administration of trial medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Afatinib Monotherapy (Part A)</title>
          <description>Afatinib 50 mg film-coated tablet was orally administered once daily of each 28-day treatment course, with dose reductions to 40 mg/day and 30 mg/day (following the protocol-defined dose reduction scheme).</description>
        </group>
        <group group_id="E2">
          <title>Afatinib Plus Paclitaxel (Part B)</title>
          <description>Afatinib 40 mg film-coated tablet dose was orally administered once daily of each 28-day treatment course, with dose reductions to 30 mg/day and 20 mg/day (following the protocol defined dose reduction scheme) plus paclitaxel 80 mg/m2 administered via intravenous infusion once weekly (7 weeks on/1 week off; 2 dose reductions were allowed following the protocol defined dose reduction scheme and the current local summary of product characteristics).</description>
        </group>
        <group group_id="E3">
          <title>Investigators Choice of Chemotherapy (Part B)</title>
          <description>Reference therapy for Part B dose: Depending on schedule Intravenous or oral administration (2 dose reductions were allowed following the protocol defined dose reduction scheme and the current local summary of product characteristics).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="471" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Tracheo-oesophageal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hypomotility</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Jejunal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vomiting projectile</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Extravasation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gravitational oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Performance status decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hepatic mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hepatic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Aspergillus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture displacement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Biopsy lymph gland abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gene mutation identification test</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Staphylococcus test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Metastases to meninges</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pericarditis malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Malignant ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of pleura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Metastases to peritoneum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Metastases to pleura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Metastatic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Tumour compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Monoplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Reversible ischaemic neurological deficit</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pleural fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Thoracic haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Skin erosion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Skin toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Lung transplant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Partial lung resection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neurogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Raynaud's phenomenon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Superior vena cava syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1129" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="964" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="252" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="303" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="211" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="200" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="200" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="342" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="304" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="194" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="194" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="179" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="629" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

